Grants and Contributions

About this information

In June 2016, as part of the Open Government Action Plan, the Treasury Board of Canada Secretariat (TBS) committed to increasing the transparency and usefulness of grants and contribution data and subsequently launched the Guidelines on the Reporting of Grants and Contributions Awards, effective April 1, 2018.

The rules and principles governing government grants and contributions are outlined in the Treasury Board Policy on Transfer Payments. Transfer payments are transfers of money, goods, services or assets made from an appropriation to individuals, organizations or other levels of government, without the federal government directly receiving goods or services in return, but which may require the recipient to provide a report or other information subsequent to receiving payment. These expenditures are reported in the Public Accounts of Canada. The major types of transfer payments are grants, contributions and \'other transfer payments\'.

Included in this category, but not to be reported under proactive disclosure of awards, are (1) transfers to other levels of government such as Equalization payments as well as Canada Health and Social Transfer payments. (2) Grants and contributions reallocated or otherwise redistributed by the recipient to third parties; and (3) information that would normally be withheld under the Access to Information Act and the Privacy Act.

Found five records

$4,000,000.00

Nov 1, 2022

For-profit organization

Agreement:

LSALT Drug Development program to mitigate COVID-19 related Organ (Lung and Kidney) damage and inflammation

Agreement Number:

1003639

Duration: from Nov 1, 2022 to Mar 31, 2024
Description:

The project targets the prevention of acute organ inflammation injury in the lungs and kidneys of patients who have moderate to severe COVID-19 and other diseases. LSALT peptide is a novel drug candidate and selective dipeptidase-1 inhibitor which blocks injury in the lungs and kidneys by reducing leukocyte recruitment and inflammation in these organs.

This project focuses on completing the clinical and commercial drug development tasks needed to obtain regulatory approval for LSALT peptide. A successful project will advance the LSALT peptide as a new therapeutic that will reduce organ inflammation complications in high risk patients, increase survival rates and provide resiliency in the Canadian healthcare system for future pandemics.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Toronto, Ontario, CA M4T 2M5

$5,407,235.00

Sep 1, 2020

For-profit organization

Agreement:

513415

Agreement Number:

513415

Duration: from Sep 1, 2020 to Mar 31, 2022
Description:

This project is to advance a lead therapeutic drug candidate through Phase II clinical trials to treat severe cases of COVID-19, specifically in the lungs, kidney and liver.

Organization: Innovation, Science and Economic Development Canada
Program Name: SIF Stream 1- R&D
Location: Toronto, Ontario, CA M4T2M5

$200,000.00

Jan 1, 2019

For-profit organization

Agreement:

Pre-clinical and Clinical Development for LSALT Peptide to Treat Inflammation and Kidney Injury

Agreement Number:

919337

Duration: from Jan 1, 2019 to Jan 29, 2021
Description:

LSALT patents have been assigned to Arch Biopartners Inc. who will manage drug development and human clinical trials for acute kidney injury as the first indication.

Organization: National Research Council Canada
Program Name: Industrial Research Assistance Program – Contributions to Firms
Location: Toronto, Ontario, CA M4T 2M5

$91,030.00

Dec 24, 2013
Organization: National Research Council Canada
Location: Toronto, Ontario, CA

$107,000.00

Mar 5, 2012
Organization: National Research Council Canada
Location: Toronto, Ontario, CA